MNKD MannKind Corporation

0.98
+0.05  (+5%)
Previous Close 0.94
Open 0.95
Price To Book -1.09
Market Cap 209,110,888
Shares 212,295,318
Volume 2,589,498
Short Ratio
Av. Daily Volume 2,759,292
Stock charts supplied by TradingView

NewsSee all news

  1. Jennifer Grancio Appointed to MannKind Board of Directors

    WESTLAKE VILLAGE, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020. Ms. Grancio

  2. MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic

    WESTLAKE VILLAGE, Calif., March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is

  3. MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results

    2019 Total Revenue of $63.0 million ° 2019 Afrezza Net Revenue of $25.3 million; +46% vs. 2018° 2019 Collaborations and Services Revenue of $37.7 million; +257% vs. 2018 4Q 2019 Total

  4. MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    WESTLAKE VILLAGE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such

  5. MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)

    WESTLAKE VILLAGE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced the presentation of results from multiple clinical studies of Afrezza® (insulin human) Inhalation Powder

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved June 27, 2014.
AFREZZA
Type 1/2 diabetes

Latest News

  1. Jennifer Grancio Appointed to MannKind Board of Directors

    WESTLAKE VILLAGE, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020. Ms. Grancio

  2. MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic

    WESTLAKE VILLAGE, Calif., March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is

  3. MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results

    2019 Total Revenue of $63.0 million ° 2019 Afrezza Net Revenue of $25.3 million; +46% vs. 2018° 2019 Collaborations and Services Revenue of $37.7 million; +257% vs. 2018 4Q 2019 Total

  4. MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    WESTLAKE VILLAGE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such

  5. MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)

    WESTLAKE VILLAGE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced the presentation of results from multiple clinical studies of Afrezza® (insulin human) Inhalation Powder

  6. MannKind Corporation to Hold 2019 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2020

    WESTLAKE VILLAGE, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2019 fourth quarter and full year financial results and its management will host a conference call to

  7. Afrezza® (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month

    WESTLAKE VILLAGE, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that its Brazilian partner, Biomm S.A., has received written notice from the Chamber of Regulation of the

  8. Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza® Relative to Insulin Aspart in Type 1 Diabetes

    WESTLAKE VILLAGE, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that Hypoglycemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1

  9. MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference

    WESTLAKE VILLAGE, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such

  10. MannKind Appoints Tony Hooper to Its Board of Directors

    WESTLAKE VILLAGE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020.  Mr. Hooper will also

  11. MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results

    3Q 2019 Total Revenues of $14.6 million; +227% vs. 3Q 2018°  3Q 2019 Afrezza Net Revenue was $6.4 million; +46% vs. 3Q 2018    •  Afrezza sold to our marketing partner in Brazil for launch was $0.7 million°  3Q 2019

  12. MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics

    WESTLAKE VILLAGE, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and

  13. MannKind Corporation to Hold 2019 Third Quarter Financial Results Conference Call on November 6, 2019

    WESTLAKE VILLAGE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2019 third quarter and year-to-date financial results and its management will host a conference call to

  14. MannKind Corporation to Present at the 2019 Cantor Global Healthcare Conference

    WESTLAKE VILLAGE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases

  15. MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD

    WESTLAKE VILLAGE, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder was presented at the 55th Annual

  16. MannKind Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference

    WESTLAKE VILLAGE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such